Cerus Corp. (NASDAQ:CERS) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the firm. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $9.10.

Several research analysts have weighed in on CERS shares. Zacks Investment Research lowered shares of Cerus Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday. Robert W. Baird restated an “outperform” rating and set a $9.00 target price on shares of Cerus Corp. in a research report on Wednesday, June 22nd. FBR & Co restated an “outperform” rating and set a $10.00 target price on shares of Cerus Corp. in a research report on Wednesday, September 7th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Cerus Corp. in a research report on Sunday, July 31st. Finally, BTIG Research restated a “buy” rating and set a $10.00 target price on shares of Cerus Corp. in a research report on Monday, June 20th.

Shares of Cerus Corp. (NASDAQ:CERS) opened at 5.90 on Wednesday. The stock’s market cap is $605.98 million. Cerus Corp. has a 52-week low of $4.27 and a 52-week high of $7.64. The stock’s 50 day moving average is $6.33 and its 200 day moving average is $6.23.

Cerus Corp. (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. Cerus Corp. had a negative return on equity of 73.14% and a negative net margin of 189.29%. The firm had revenue of $9.25 million for the quarter, compared to analyst estimates of $8.88 million. During the same quarter last year, the firm earned ($0.17) earnings per share. The company’s revenue was up 4.8% compared to the same quarter last year. On average, equities analysts expect that Cerus Corp. will post ($0.68) earnings per share for the current fiscal year.

In other news, CFO Kevin Dennis Green sold 17,150 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $6.80, for a total value of $116,620.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 6.60% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. raised its stake in Cerus Corp. by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,559,771 shares of the company’s stock valued at $15,179,000 after buying an additional 15,881 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Cerus Corp. by 116.6% in the second quarter. Janney Montgomery Scott LLC now owns 111,967 shares of the company’s stock valued at $702,000 after buying an additional 60,267 shares in the last quarter. Kennedy Capital Management Inc. acquired a new stake in Cerus Corp. during the first quarter valued at approximately $5,390,000. Cortina Asset Management LLC raised its stake in Cerus Corp. by 37.3% in the second quarter. Cortina Asset Management LLC now owns 1,133,537 shares of the company’s stock valued at $7,073,000 after buying an additional 307,941 shares in the last quarter. Finally, First Midwest Bank Trust Division raised its stake in Cerus Corp. by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 415,292 shares of the company’s stock valued at $2,591,000 after buying an additional 110,275 shares in the last quarter. Institutional investors and hedge funds own 67.01% of the company’s stock.

About Cerus Corp.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

5 Day Chart for NASDAQ:CERS

Receive News & Stock Ratings for Cerus Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corp. and related stocks with our FREE daily email newsletter.